A 21 Day Pharmacokinetics Study in Papulopustular Rosacea

Completed · Phase 1

Conditions studied: Papulopustular Rosacea

In brief

The purpose of this study is to characterize the pharmacokinetics of once daily topical gel and confirm that steady state conditions are reached under maximal use conditions following 3 weeks of daily applications.

Key facts

Study ID

NCT02028286

Run by

Maruho Co., Ltd.

People needed

25

Starts

2014-01-01

Last updated by the study team

2014-04-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• A diagnosis of papulopustular rosacea
• Grade 3 or 4 on the 5-point Investigator Global Assessment scale
• Presence of telangiectasia

You may not qualify if…

• steroid rosacea or subtype 3 (phymatous rosacea)
• clinically significant abnormal findings that would interfere with study objective or risk to safety for the subject.
• nodular rosacea (lesions greater than 5mm with more than 2 modules)

Where it is running

• Frontage Clinical Services — Hackensack, New Jersey, United States
• Derm Research — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.